Literature DB >> 11691530

Initial energy setting, outcome and efficiency in direct current cardioversion of atrial fibrillation and flutter.

M M Gallagher1, X H Guo, J D Poloniecki, Y Guan Yap, D Ward, A J Camm.   

Abstract

OBJECTIVES: The purpose of this study was to design a more efficient protocol for the electrical cardioversion of atrial arrhythmias.
BACKGROUND: Guidelines for electrical cardioversion of atrial arrhythmias recommend starting with low energy shocks, which are often ineffective.
METHODS: We recorded the sequence of shocks in 1,838 attempts at cardioversion for atrial fibrillation (AF) and 678 attempts at cardioversion for atrial flutter. These data were used to calculate the probability of success for each shock of a standard series and the probability of success with a single shock at each intensity. In 150 cases, a rhythm strip with the time of each shock allowed us to calculate the time expended on unsuccessful shocks.
RESULTS: We analyzed the effects of 5,152 shocks delivered to patients for AF and 1,238 shocks delivered to patients for atrial flutter. The probability of success on the first shock in AF of > 30 days duration was 5.5% at < 200 J, 35% at 200 J and 56% at 360 J. In atrial flutter, an initial 100 J shock worked in 68%. In AF of >30 days duration, shocks of < 200 J had a 6.1% probability of success; this fell to 2.2% with a duration >180 days. In those with AF for >180 days, the initial use of a 360 J shock was associated with the eventual use of less electrical energy than with an initial shock of < or =100 J (581 +/- 316 J vs. 758 +/- 433 J, p < 0.01, Mann-Whitney U test).
CONCLUSIONS: An initial energy setting of > or =360 J can achieve cardioversion of AF more efficiently in patients than traditional protocols, particularly with AF of longer duration.

Entities:  

Mesh:

Year:  2001        PMID: 11691530     DOI: 10.1016/s0735-1097(01)01540-6

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  16 in total

1.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  Circulation       Date:  2014-03-28       Impact factor: 29.690

2.  Direct Current Cardioversion of Atrial Arrhythmias in Adults With Cardiac Amyloidosis.

Authors:  Edward A El-Am; Angela Dispenzieri; Rowlens M Melduni; Naser M Ammash; Roger D White; David O Hodge; Peter A Noseworthy; Grace Lin; Sorin V Pislaru; Alexander C Egbe; Martha Grogan; Vuyisile T Nkomo
Journal:  J Am Coll Cardiol       Date:  2019-02-12       Impact factor: 24.094

3.  Atrial Flutter, Typical and Atypical: A Review.

Authors:  Francisco G Cosío
Journal:  Arrhythm Electrophysiol Rev       Date:  2017-06

4.  Association between transthoracic impedance and electrical cardioversion success with biphasic defibrillators: An analysis of 1055 shocks for atrial fibrillation and flutter.

Authors:  Mouhannad M Sadek; Varsha Chaugai; Mark J Cleland; Timothy J Zakutney; David H Birnie; F Daniel Ramirez
Journal:  Clin Cardiol       Date:  2018-05-11       Impact factor: 2.882

5.  A Comparison Between Dabigatran and Warfarin on Time to Elective Cardioversion.

Authors:  Amanda N Basto; Nathan P Fewel; Rajiv Gupta; Eileen M Stock; Mia Mia Ta
Journal:  J Atr Fibrillation       Date:  2016-04-30

Review 6.  Electric cardioversion of atrial fibrillation.

Authors:  Maen Nusair; Greg C Flaker; Anand Chockalingam
Journal:  Mo Med       Date:  2010 Jan-Feb

Review 7.  Atrial fibrillation: choosing an antiarrhythmic drug.

Authors:  Todd Rudo; Peter Kowey
Journal:  Curr Cardiol Rep       Date:  2006-09       Impact factor: 2.931

8.  Low molecular weight heparin (parnaparin) for cardioembolic events prevention in patients with atrial fibrillation undergoing elective electrical cardioversion: a prospective cohort study.

Authors:  Giulia Angeloni; Silvia Alberti; Enrico Romagnoli; Alberto Banzato; Marco Formichi; Umberto Cucchini; Vittorio Pengo
Journal:  Intern Emerg Med       Date:  2010-11-17       Impact factor: 3.397

9.  Higher energy monophasic DC cardioversion for persistent atrial fibrillation: is it time to start at 360 joules?

Authors:  C Boos; M D Thomas; A Jones; E Clarke; G Wilbourne; R S More
Journal:  Ann Noninvasive Electrocardiol       Date:  2003-04       Impact factor: 1.468

10.  Comparison of monophasic and biphasic shocks for transthoracic cardioversion of atrial fibrillation.

Authors:  M Scholten; T Szili-Torok; P Klootwijk; L Jordaens
Journal:  Heart       Date:  2003-09       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.